Status:
COMPLETED
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
House Dust Mite Allergy
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis
Eligibility Criteria
Inclusion
- Positive skin prick test to house dust mite,
- Positive RAST test to house dust mite,
- Positive provocation test result to house dust mite,
Exclusion
- Serious chronic diseases,
- Other perennial allergies
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00263549
Start Date
September 1 2002
End Date
February 1 2006
Last Update
February 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465